Valuation: NEOVACS

Market Cap 4.09T 4.68T 3.76T 3.5T 6.64T 4L 6.74T 45.07T 17.54T 2L 17.55T 17.17T 8L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.19Cr -3L -22.15L -9L -1.08Cr -9L -8L -3.71Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 2L
+1.70%+7.41%+2.50%+8.22% 4.99TCr
+0.92%+3.93%+399.71%+605.33% 4.02TCr
+1.89%+8.32%+26.06%-6.35% 3.46TCr
+2.38%+6.35%+21.25%+64.58% 3.31TCr
+3.96%+10.67%+8.30%+40.44% 2.75TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+133.27% 1.59TCr
+0.32%+0.58%+14.00%+19.59% 1.39TCr
+3.30%+0.76%+90.23%+99.12% 1.35TCr
Average +1.86%+5.82%+79.44%+120.52% 2.73TCr
Weighted average by Cap. +2.07%+6.53%+90.20%+137.91%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.81Cr 9L 58.79L 22.87L 2.86Cr 22.89L 22.4L 9.85Cr 4L 5L 4L 4L 7L 4.73Cr 7L 47.83L 18.61L 2.32Cr 18.62L 18.22L 8.01Cr
Net income -87.43L -99.97L -80.37L -74.9L -1.42Cr -95Cr -1.44Cr -9.64Cr -3.75Cr -47Cr -3.75Cr -3.67Cr -161.41Cr -3.29Cr -3.76Cr -3.03Cr -2.82Cr -5.35Cr -358.47Cr -5.43Cr -36Cr -14Cr -176.2Cr -14Cr -14Cr -607.61Cr
Net Debt -2L -3L -2L -2L -4L -2.58Cr -4L -26.07L -10.14L -1.27Cr -10.15L -10L -4.37Cr -2L -2L -2L -2L -3L -2.23Cr -3L -22.6L -9L -1.1Cr -9L -9L -3.79Cr
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-